Truist analyst Asthika Goonewardene lowered the firm’s price target on Hookipa Pharma to $4 from $11 but keeps a Buy rating on the shares. The analyst is adjusting the firm’s model on the stock – removing HB-101, adjusting timelines for HB-200, and making an "overdue reassessment of peak, price, and penetration". The firm adds however that the data coming up for Hookipa’s lead program – particularly PFS and Durability – will be key to assessing its synergy with PD-1 – which appears discounted at current share prices.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HOOK:
- HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
- Hookipa Pharma reports Q4 EPS (17c), consensus (21c)
- Hookipa Pharma appoints Terry Coelho to board of directors
- HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
- Hookipa Pharma achieves $10M milestone payment under Roche collaboration